Dr. Vaibhav Agrawal

Claim this profile

City of Hope Medical Center

Studies Myelodysplastic Syndrome
Studies Acute Myelogenous Leukemia
2 reported clinical trials
4 drugs studied

Area of expertise

1

Myelodysplastic Syndrome

Vaibhav Agrawal has run 2 trials for Myelodysplastic Syndrome. Some of their research focus areas include:

HLA-A positive
HLA-A negative
HLA positive
2

Acute Myelogenous Leukemia

Vaibhav Agrawal has run 2 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:

HLA-A positive
HLA-A negative
HLA positive

Affiliated Hospitals

Image of trial facility.

City Of Hope Medical Center

Clinical Trials Vaibhav Agrawal is currently running

Image of trial facility.

CMV-MVA Triplex Vaccine

for Blood Cancers

This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. The CMV-MVA Triplex vaccine works by causing an immune response in the donors body to the CMV virus, creating immunity to it. The donor then passes that immunity on to the patient upon receiving the stem cell transplant. Giving the CMV-MVA triplex vaccine to donors may help prevent CMV infection of patients undergoing stem cell transplantation.

Recruiting

0 awards

Phase 2

23 criteria

Image of trial facility.

Pembrolizumab + Decitabine with or without Venetoclax

for Acute Myeloid Leukemia or Myelodysplastic Syndrome

This phase Ib trial studies the side effects and best dose of pembrolizumab and how well it works in combination with decitabine with or without venetoclax in treating patients with acute myeloid leukemia or myelodysplastic syndrome that is newly-diagnosed, has come back (recurrent), or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. This trial may help doctors find the best dose of pembrolizumab that can be safely given in combination with decitabine with or without venetoclax, and to determine what side effects are seen with this treatment.

Recruiting

3 awards

Phase 1

1 criteria

More about Vaibhav Agrawal

Clinical Trial Related

1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Vaibhav Agrawal has experience with

  • Decitabine
  • Pembrolizumab
  • Venetoclax
  • CMV-MVA Triplex Vaccine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Vaibhav Agrawal specialize in?

Is Vaibhav Agrawal currently recruiting for clinical trials?

Are there any treatments that Vaibhav Agrawal has studied deeply?

What is the best way to schedule an appointment with Vaibhav Agrawal?

What is the office address of Vaibhav Agrawal?

Is there any support for travel costs?